Manal Elnenaei

Associate Professor

Phone: 902-473-5194
Fax: 902-473- 2123
Mailing Address: 
Room 616 Mackenzie Building
5788 University Avenue
Halifax, NS, B3H 1V8

Curriculum vitae (PDF; June 2017)

Degrees & Professional Designations

  • European Specialist in Laboratory Medicine (EuSpLM), 2012.
  • Certificate of Completion of Training (CCST), General Medical Council, UK, 2010.
  • Fellowship of the Royal College of Pathologists, UK (FRCPath), 2010.
  • PhD in Pathology, University of London (Topic: Genetic Characterization of Multiple Myeloma), 2002.
  • Masters in Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Egypt, 1995.
  • Bachelor of Medicine and Surgery (MBChB), with Distinction, Faculty of Medicine, University of Alexandria, Egypt, 1989.

Areas of Clinical / Research Interests

Multiple Myeloma

Dr. Elnenaei has co-led the initiative of a Myeloma Tumor Bank and Database. This project has brought together a multidisciplinary team comprising Dalhousie Faculty as well Clinician Scientists, to focus on translational research in Multiple Myeloma. Objectives of this research include a joint focus on clinical genetics and immunology for patients with MM and leveraging our unique, multidisciplinary expertise to create faithful models of cancer, establish and test new treatment modalities.

Clinical Research

Dr. Elnenaei is working closely with the endocrine team to establish local guidelines that enhance clinical value in laboratory testing. She has recently set up a system by which reflex strategies by laboratory informatics enables reflective testing by the medical biochemist and subsequent early diagnosis and notification of certain endocrine conditions.

Appropriate test utilization is a strong area of interest for Dr. Elnenaei and is part of the NSHA Choosing Wisely group. A number of initiatives in this area have produced substantial savings by reducing the number of unnecessary tests produced by the laboratory. She is also working closely with the Dalhousie Health Informatics team on initiatives that have a broader stakeholder impact.

Selected Publications

  1. Lou AH, Elnenaei MO, Sadek I, Thompson S, Crocker BD, Nassar BA. Multiple pre- and post-analytical lean approaches to the improvement of the laboratory turnaround time in a large core laboratory. Clin Biochem. S0009-9120(17)30328-4.
  2. Elnenaei MO , Campbell SG , Thoni AJ,  Lou A , Crocker BD, Nassar BA An effective utilization management strategy by dual approach of influencing physician ordering and gate keeping. Clin Biochem. 2016;49:208-12.
  3. Elnenaei MO, Alaghband-Zadeh J, Sherwood R, Awara MA, Moniz C, Le Roux CW. Leptin and IGF1; diagnostic markers of re-feeding syndrome and mortality. Br J Nutr. 2011 May 4:1-7. 
  4. Elnenaei MO, Chandra R, Moniz C. Genotyping of VDR and ER predicts response to oral calcium and vitamin D and correlates with results of NMR pattern recognition- an observational study. Br J Nutr. 2010 Aug; 23:1-8.
  5. Elnenaei MO, Musto R, Alaghband-Zadeh J, Moniz C, Le Roux CW. Postprandial bone turnover is independent of calories above 250 kcal. Ann Clin Biochem. 2010 Jul;47: 318-20
  6. Elnenaei MO, Gruszka-Westwood AM, A'Hernt R, Matutes E, Sirohi B, Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A. Haematologica. 2003 May;88(5):529-37.
  7. Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E, Catovsky D. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes Chromosomes Cancer. 2003 Jan;36(1):99-106.
  8. Elnenaei MO, Jadayel DM, Matutes E, Morilla R, Owusu-Ankomah  K, Atkinson S, Titley I, Mandala EM, Catovsky D. Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies. Leuk Res. 2001 Feb;25(2):115-23.